Statistical aspects in comparative benefit-risk assessment: Challenges and opportunities for pharmaceutical statisticians

Pharmaceutical Statistics

Volumn 11, Issue 1, 2012, Pages 82-85

  Quartey, George ^a   Wang, Jixian ^b  

^a Statistics Methods and Research Group   (United Kingdom)

^b Novartis ^*  (Switzerland)

Author keywords

benefit risk; comparative benefit risk; quantitative benefit risk methods

Indexed keywords

DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HEALTH CARE COST; HEALTH ECONOMICS; PROBABILITY; REVIEW; RISK BENEFIT ANALYSIS; SIMULATION; STATISTICS;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG DESIGN; DRUG INDUSTRY; HEALTH CARE COSTS; HUMANS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT;

EID: 84856557339     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.497     Document Type: Review

References (34)

1. Mussen F, Salek S, Walker S,. 2009. Concept and scope of benefit-risk evaluation of medicines, In In Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-making (Chapter 1)., Mussen F, Salek S, Walker S, (eds), John Wiley & Sons Ltd Publisher.
2. Wysowski DK, Swartz L,. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005 165: 1363-9.
3. FDA. FDA Amendment Act 2007. Available from: [Accessed January 2, 2009].
4. Strom BL,. How the US drug safety system should be changed. JAMA 2006 295: 2072-5. (Pubitemid 44794008)
5. Ray WA, Stein CM,. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 2006 354: 194-201. (Pubitemid 43076719)
6. Mancini GBJ, Schulzer M,. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation 1999 99: 377-83. (Pubitemid 29051263)
7. Grieve AP,. The number needed to treat: a useful clinical measure of a case of the Emperor's new clothes?. Pharmaceutical Statistics 2003 2: 87-102.
8. Holden WL, Juhaeri J, Dai W,. Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiololgy Drug Safety 2003 12: 611-16. (Pubitemid 37220648)
9. Holden WL, Juhaeri J, Dai W,. Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiology Drug Safety 2003 12: 693-7. (Pubitemid 38028784)
10. Holden WL,. Benefit-risk analysis: a brief review and proposed quantitative approaches. Drug Safety 2003 26 (12): 853-862. (Pubitemid 37188248)
11. Chuang-Stein C,. A new proposal for benefit-less-risk analysis in clinical trials. Controlled Clinical Trials 1994 15: 30-43. (Pubitemid 24078603)
12. Chuang-Stein C,. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Statistics in Medicine 1991 10: 1349-1359.
13. Pritchett YL, Tamura R,. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method. Pharmaceutical Statistics 2008 7: 170-8.
14. Gelber RD, Goldhirsch A, Cole BF,. Evaluation of effectiveness: Q-TwiST. Cancer Treat Rev 1993 19 (Suppl. A): S73-84.
15. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008 99: 711-15.
16. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989 7: 36-44. (Pubitemid 19089079)
17. Edwards R, Wiholm BE, Martinez C,. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Saf 1996 15: 89-95.
18. CIOMS Working Group IV. Benefit-risk Balance for Marketed Drugs: Evaluating Safety Signals, CIOMS, 1998. Geneva.
19. Beckmann J,. Basic aspects of risk-benefit analysis. Seminars in Thrombosis and Hemostatsis 1999 25: 89-95.
20. Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R,. The clinical utility index as a practical multiattribute approach to drug development decisions:. Clinical pharmacology & Therapeutics 2009 86: 105-108.
21. Mussen F, Salek S, Walker S,. A quantitative approach to benefit-risk assessment of medicines-part 1: development of a new model using multi-criteria decision analysis. Pharmacoepidemiology and Drug Safety 2007 16: S2-S15. (Pubitemid 47180358)
22. Garrison L,. A structured health outcomes approach to the pre-marketing quantitative risk-benefit modeling of new pharmaceuticals. Presented at the Benefit-Risk Assessment for Drugs Workshop. Office of Health Economics, 24 October 2007, London, UK.
23. Johnson FR, Hauber AB,. Quantitative risk-benefit analysis for regulatory decision making:Alternatives and challenges. Presented at the Benefit-risk Assessments for Drugs Workshops. Office of Health Economics, 24 October 2007, London, UK.
24. Shaffer ML, Watterberg KL,. Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Med Res Methodol 2006 6: 48.
25. Lynd LD, O'Brien BJ,. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol 2004 57: 795-803. (Pubitemid 39370162)
26. Shakespeare TP, Gebski VJ, Veness MJ, Simes J,. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet 2001 357: 1349-53. (Pubitemid 32441538)
27. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW,. A Review of Quantitative Risk-Benefit Methodologies for Assessing Drug Safety and Efficacy-Report of the ISPOR Risk-Benefit Management Working Group Value in Health. 2010. [Epub ahead of print].
28. Ray WA, Stein CM,. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 2006 354: 194-201. (Pubitemid 43076719)
29. Schmitt S, Lis Y, Carter M,. 2008. Benefit risk assessment during research and development., In In Risk-Based Compliance Handbook (Chapter 7), Schmitt S, (ed).
30. Okie S,. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 2005 352: 1173-6. (Pubitemid 40397257)
31. Veatch RM,. Benefit risk assessment: what patients can know that scientists cannot. Drug Info J 1993 27: 1021-9. (Pubitemid 23345405)
32. Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H,. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of Oncology 2005 16: 1458-1462. (Pubitemid 41222418)
33. Kirkwood CW,. Strategic Decision Making: Multiobjective Decision Analysis with Spreadsheets, Wadsworth Publishing Co: Belmont, CA, USA, 1996.
34. Keeney RL,. Value-Focused Thinking: A Path to Creative Decision-making, Harvard University Press: Cambridge, MA, USA, 1992.